MPA (n=49) | MPA eligible* (n=393) | Age-sex adjusted | PSOW adjusted† | |||
Effect size (95% CI) | P value | Effect size (95% CI) | P value | |||
Severity | 0.038 | 0.88 | ||||
Mild | 26 (53.1) | 211 (53.7) | 1.00 (ref.) | – | 1.00 (ref.) | – |
Moderate | 14 (28.6) | 126 (32.1) | 1.39 (0.67 to 2.88)‡ | 0.37 | 0.83 (0.27 to 2.50)‡ | 0.74 |
Severe | 9 (18.4) | 56 (14.3) | 3.43 (1.33 to 8.83)‡ | 0.011 | 1.20 (0.32 to 4.40)‡ | 0.78 |
Length of hospital stay, median (IQR) | 9.0 (4.0 to 19.0) | 10.0 (6.0 to 32.0) | 0.74 (0.42 to 1.31)§ | 0.30 | 0.93 (0.42 to 2.05)§ | 0.86 |
Death | 6 (12.2) | 37 (9.4) | 4.94 (1.59 to 15.34)‡ | 0.006 | 1.31 (0.28 to 5.95)‡ | 0.73 |
Values are presented as n (percentage) unless otherwise indicated. Values, effect size and p values were calculated after handle missing data by simple imputation.
*The MPA eligible group included patients in the no MPA treatment group who did not receive treatment despite having diseases for which treatment is a recognised therapeutic option.
†Effect size and p values calculated using propensity score overlap weighting analyses, using MPA eligible subgroup as reference.
‡OR calculated using multinomial or binary logistic regression models.
§Sub-HR (sHR) calculated among 205 hospitalised patients using Fine and Gray model with discharge alive as the event of interest and hospital death as the competing event. sHR >1 indicates an increase in length of hospital stay, and an sHR <1 indicates a decrease in length of hospital stay compared with the reference group.
MPA, mycophenolic acid; PSOW, propensity score overlap weighting;